Pancreatic Cancer Research

ResearcherHeidelberg UniversityActive in the last 2 years

Michael Schaefer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5614-7296; OpenAlex author ID A5101784329. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Baicalein disrupts TGF-β-induced EMT in pancreatic cancer by FTO-dependent m6A demethylation of ZEB1. Co-author DOI 10.1016/j.bbamcr.2025.119969↗
  2. Corrigendum: Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1343421↗
  3. Corrigendum to: "Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death" [Biomed. Pharmacother. 153 (2… Co-author DOI 10.1016/j.biopha.2023.115879↗
  4. Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death. Co-author DOI 10.1016/j.biopha.2022.113511↗
  5. Glucocorticoid-induced microRNA-378 signaling mediates the progression of pancreatic cancer by enhancing autophagy. Co-author DOI 10.1038/s41419-022-05503-3↗
  6. Corrigendum: Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.889215↗
  7. Therapy of pancreatic cancer with alternating electric fields: Limitations of the method. Last author DOI 10.1016/j.bioelechem.2021.107881↗
  8. Establishment of Tumor Treating Fields Combined With Mild Hyperthermia as Novel Supporting Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.738801↗
  9. Alpha-Lipoic Acid Prevents Side Effects of Therapeutic Nanosilver without Compromising Cytotoxicity in Experimental Pancreatic Cancer. Co-author DOI 10.3390/cancers13194770↗
  10. Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication. Co-author DOI 10.18632/oncotarget.1764↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Herr · 10 shared papers, 2014–2025 · strength 1.62
  2. Bin Yan · 4 shared papers, 2021–2025 · strength 0.77
  3. Li Liu · 5 shared papers, 2014–2024 · strength 0.69
  4. Tobias Pfeifer · 4 shared papers, 2021–2024 · strength 0.68
  5. Liping Bai · 4 shared papers, 2021–2024 · strength 0.68
  6. Xuefeng An · 4 shared papers, 2021–2023 · strength 0.62
  7. Kangtao Wang · 2 shared papers, 2021–2025 · strength 0.41
  8. Li Liu · 2 shared papers, 2021–2023 · strength 0.34
  9. Chen Gong · 1 shared paper, 2025 · strength 0.28
  10. Lian Zhao · 1 shared paper, 2025 · strength 0.28
  11. Li Liu · 1 shared paper, 2022 · strength 0.16
  12. Li Liu · 1 shared paper, 2022 · strength 0.14
  13. Xi Xiao · 1 shared paper, 2022 · strength 0.14
  14. Oliver Strobel · 1 shared paper, 2022 · strength 0.14
  15. Yiqiao Luo · 1 shared paper, 2021 · strength 0.12
  16. Clifford C. Nwaeburu · 1 shared paper, 2014 · strength 0.03
  17. Tobias Förster · 1 shared paper, 2014 · strength 0.03
  18. Nathalia A. Giese · 1 shared paper, 2014 · strength 0.03
  19. Peter Schemmer · 1 shared paper, 2014 · strength 0.03
  20. Orkhan Isayev · 1 shared paper, 2014 · strength 0.03
  21. Yiyao Zhang · 1 shared paper, 2014 · strength 0.03
  22. Jens Werner · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.